Actively Recruiting
Study of Genomic and Methylation Patterns in Adults with Extensive-Stage Small Cell Lung Cancer and Metastatic Large Cell Neuroendocrine Carcinoma Undergoing Chemo-Immunotherapy
Led by Oncology Center of Biochemical Education And Research · Updated on 2025-03-19
111
Participants Needed
2
Research Sites
36 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating how genetic and epigenetic factors contribute to resistance against chemo-immunotherapy in adults with extensive-stage small cell lung cancer ES-SCLC or metastatic large cell neuroendocrine carcinoma LCNEC. These aggressive lung cancers have limited treatment options, and most patients develop resistance to therapy within a few months, leading to disease progression and poor survival. The study aims to discover molecular changes that cause resistance, which may help guide future personalized treatments. Participants receive standard chemo-immunotherapy treatments, including platinum-based chemotherapy cisplatin or carboplatin combined with immune checkpoint inhibitors like atezolizumab or durvalumab. Biospecimens such as blood and tumor tissue are collected before treatment, during therapy every 9 weeks, and at disease progression, including optional re-biopsies. These samples are analyzed for genomic, epigenetic, methylation, and transcriptomic signatures to identify patterns related to treatment resistance and tumor evolution. Throughout the three-year study, participants undergo clinical evaluations, imaging scans, and blood draws to monitor tumor response and disease status. Researchers assess circulating tumor cells, tumor DNA, and immune markers to understand how these relate to progression and survival. This detailed monitoring aims to identify biomarkers that predict resistance and improve treatment strategies for these difficult cancers, supporting the development of more precise and effective therapies.
CONDITIONS
Brief Title
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here